Treatment outcomes and response pattern of ustekinumab in Korean patients with psoriasis: a retrospective single center study = Treatment outcomes and response pattern of ustekinumab in Korean patients with psoriasis: a retrospective single center study

다국어 초록 (Multilingual Abstract)

Background: Psoriasis is a chronic immune-mediated inflammatory skin disease affecting 2-3% of worldwide population. Ustekinumab, an IL-12/23p40 inhibitor, is a biologic reported to be effective and safe in treating psoriasis. However, there are limited data showing treatment outcomes of ustekinumab in patients with psoriasis in Korea.
Objectives: To evaluate the treatment outcomes and response pattern of ustekinumab in patients with psoriasis in Korea.
Methods: This study was a retrospective single-center study. 84 patients with psoriasis treated with ustekinumab were analyzed. Each patient’s medical records, PASI score, BSA were reviewed at baseline and up to week 52.
Results: In total, 84 patients were included (male:female=1.8:1). The mean age was 44.5 years. At week 16, 86.7% achieved PASI75, 59.0% achieved PASI90 and 20.5% achieved PASI100. By week 16, 84.8% of subjects had attained PASI75 for the head region, whereas 79.0% had attained it for lower extremities, indicating relatively slower treatment response of psoriatic lesions on lower extremities. 4 patients discontinued treatment due to lack of effect. There was no severe adverse event during follow-up period.
Conclusion: Ustekinumab demonstrated highly effective and safe treatment profiles in Korean psoriatic patients consistent with the previous reports mainly from Western countries. Ustekinumab reduced skin lesions most effectively on the head region at time of week 16.